Other Clinical Trial - A Clinical Trial of COVAC-2 in Healthy Adults

Status Completed

Clinical Trial Summary

VIDO has developed a vaccine called COVAC-2. The study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The SWE adjuvant belongs to a family of oil-based adjuvants that have been given to millions of people around the world as part of influenza vaccines. The COVAC-2 vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent or reduce the severity of COVID-19 illness. In animal studies, the immune response generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection. Phase 1 is a multi-centred trial of the COVAC-2 vaccine to be completed in Canada. It will be a randomized, observer-blinded, and placebo-controlled study to assess the safety and immunogenicity of three dosing levels (25, 50, and 100 µg protein) administered twice (4 weeks apart) in healthy adults 18 through 54 years of age (Phase 1a) and 55 years of age and older (Phase 1b). Enrolment and vaccination of participants will be staggered over time based on participant age and vaccine dose. Approval will be sought from the Data Safety Monitoring Board (DSMB) to proceed with the second dose in each group, to enroll at each dose level, and to enroll in the older age group for each dose level. Within the same age group, the 8 participants receiving the lowest dose are randomized with 4 participants receiving placebo; the 8 participants receiving the medium dose are randomized with 4 participants receiving placebo; and the 8 participants receiving the highest dose are randomized with 4 participants receiving placebo. Within each dose level of 12 participants, it is proposed to immunize a first cohort of 3 participants (including at least 2 active vaccine participants) and pending no holding rule is met after 48 hours, to immunize the remaining 9 participants within that dose level.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome Coronavirus 2

Clinical Trial Details

NCT number	NCT04702178
Study type	Interventional
Source	University of Saskatchewan
Contact
Status	Completed
Phase	Phase 1
Start date	February 10, 2021
Completion date	November 2, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05543616` - A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children	Phase 2/Phase 3
Recruiting	`NCT04516811` - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19	Phase 3
Completed	`NCT04334044` - Treatment of SARS Caused by COVID-19 With Ruxolitinib	Phase 1/Phase 2
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Recruiting	`NCT04466241` - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial	Phase 2/Phase 3
Withdrawn	`NCT04381923` - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia	N/A
Recruiting	`NCT04402879` - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals	N/A
Recruiting	`NCT04661631` - Surgery and Lung Ultrasound in COVID-19 Infection
Completed	`NCT04376476` - Host-pathogen Interactions During SARS-CoV-2 Infection	N/A
Completed	`NCT04375098` - Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection	Phase 2
Completed	`NCT04402060` - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19	Phase 1/Phase 2
Active, not recruiting	`NCT04365101` - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19	Phase 1/Phase 2
Completed	`NCT04354779` - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting	`NCT04367207` - African Covid-19 Critical Care Outcomes Study
Terminated	`NCT04409873` - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)	Phase 2
Completed	`NCT04602351` - Communication in ICU During COVID-19
Terminated	`NCT04707703` - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis	Phase 3
Active, not recruiting	`NCT04987528` - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed	`NCT04667936` - Evaluation of Sedation in COVID-19 ARDS
Completed	`NCT04423770` - COVID-19 Related Health and Infection Control Practices Among Dentists

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.